National Institutes of Health
|
National Institute of Diabetes and Digestive and Kidney Diseases
Drug-Induced Liver Injury Network
Site Map |
PDF Help |
Accessibility |
Privacy Notice
What is DILIN?
Patients
Retrospective Study
Prospective Study
Participate
Practitioners
Eligibility Criteria
Retrospective Study
Prospective Study
Researchers
DILIN Overview
Retrospective
Prospective
Ancillary Studies
Clinical Sites
North Carolina
Connecticut
Michigan
Indiana
California
Resources
Presentations
NIDDK
Presentations
DILIN Overview
(pps)
Paul Watkins, MD - University of North Carolina Hospitals
Amoxicillin/Clavulanic Acid (Augmentin) Hepatotoxicity
(pps)
John McHutchison, MD - Duke University
Phenytoin Sodium
(pps)
Naga Chalasani, MD - Indiana University School of Medicine
"ACG 2006 Presentation-DILIN Prospective Study - Initial Results"
- Naga Chalasani, MD, American College of Gastroenterology, Las Vegas, NV, October 20-25, 2006
Relationship of Biochemical to Histologic Findings and the Pathological Pattern of Injury Among Cases Identified in the NIH Drug-Induced Liver Injury Network (DILIN) Study
Comparison of a Structured Causality Assessment Process Using Expert Opinion to RUCAM in Drug-Induced Liver Injury
To Top
Home
|
Patients
|
Clinical Sites
|
Practitioners
|
Researchers
|
Resources
|
Site Map